Benzinga | Aug 6, 2021 10:09AM EDT

Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases

* Ocular Therapeutix Inc (NASDAQ:OCUL) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have terminated the option and license agreement collaboration. The termination is effective immediately.

* The collaboration with Regeneron was initially formed in 2016 to develop and commercialize products containing Ocular's sustained-release hydrogel technology in combination with Regeneron's large molecule vascular endothelial growth factor for eye diseases.

* Under a 2020 amendment, the companies' efforts have focused on R&D of an extended-delivery formulation of aflibercept to be delivered to the suprachoroidal space to treat retinal diseases.

* Price Action: OCUL shares traded 3.04% lower at $10.51 and on the last check Friday.